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Abstract
Background: We tested the hypothesis that the stretch-activated, four-transmembrane domain, two pore potassium
channels (K2P), TREK-1 and TRAAK are gestationally-regulated in human myometrium and contribute to uterine relaxation
during pregnancy until labor.
Methodology: We determined the gene and protein expression of K2P channels in non-pregnant, pregnant term and
preterm laboring myometrium. We employed both molecular biological and functional studies of K2P channels in
myometrial samples taken from women undergoing cesarean delivery of a fetus.
Principal Findings: TREK-1, but not TREK-2, channels are expressed in human myometrium and significantly up-regulated
during pregnancy. Down-regulation of TREK-1 message was seen by Q-PCR in laboring tissues consistent with a role for
TREK-1 in maintaining uterine quiescence prior to labor. The TRAAK channel was unregulated in the same women. Blockade
of stretch-activated channels with a channel non-specific tarantula toxin (GsMTx-4) or the more specific TREK-1 antagonist L-
methionine ethyl ester altered contractile frequency in a dose-dependent manner in pregnant myometrium. Arachidonic
acid treatment lowered contractile tension an effect blocked by fluphenazine. Functional studies are consistent with a role
for TREK-1 in uterine quiescence.
Conclusions: We provide evidence supporting a role for TREK-1 in contributing to uterine quiescence during gestation and
hypothesize that dysregulation of this mechanism may underlie certain cases of spontaneous pre-term birth.
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Introduction
Premature birth is now the leading cause of newborn death
worldwide [1] and comparable to the number of deaths from
HIV/AIDS [2]. It accounts for 12% of all live births in the United
States [3], 75% of all perinatal complications, the leading cause of
fetal death [4] and is inexplicably more likely to occur in African
American mothers [5]. Hospital charges for premature infants in
the United States are 10 times that of a typical newborn [6] and
the costs to society in the U.S.A. are estimated by the Institute of
Medicine at $62 billion annually [7]. Despite improvements in
prenatal, perinatal and neonatal care, the incidence of premature
birth persists and is increasing [4]. To date, there is no effective
means of treatment to prevent preterm delivery [8]. Indeed, until
the development of the oxytocin receptor antagonist atociban
(TractocileH, Ferring Pharmaceuticals), no treatment was devel-
oped specifically based on myometrial pharmacology, the
introduction of the b2 adrenergic agonist ritodrine notwithstand-
ing. Administration of 17-hydroxyprogesterone caproate (17P) has
held promise in the early clinical trial setting but it does not
improve outcomes in twin pregnancies [9], nor does it appear to
be generally useful in the clinical setting [10] although certain
groups of patients may benefit [11]. Since the trigger(s) for preterm
labor are not exclusively the actions of oxytocin and the enhanced
contractility of laboring human myometrium is not all blocked by
atosiban [12], the drug has not offered a major therapeutic
advance. Treatment of mothers with so-called tocolytics (MgSO4,
terbutaline, nifedipine) is ineffective beyond 48 hours and not
without consequence [13,14]. Indeed, the therapeutic focus of
tocolytic use is providing time to employ steroid to mature the fetal
lung rather than preventing delivery until term. It is imperative
that we understand the unique physiological mechanisms
underlying pregnancy and parturition at the biochemical and
molecular level in order to discover new approaches to the
prevention of preterm labor.
We previously reported that calcium-activated potassium
channels (KCa) are differentially regulated during gestation and
suggested these channels as putative nitrosylation targets [15,16].
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muscle have suggested that part of the hyperpolarizing effects of
NO may be mediated by stretch-activated potassium (K2P)
channels [17]. These mechanosensitive potassium channels are
thought to help maintain relaxation of myocytes in visceral hollow
organs by hyperpolarizing the membrane and have been found to
regulate responses to nitrergic stimulation [18]. Although claimed
to be absent in murine myometrium [18], we have described the
expression of the potassium channels, subfamily K, member 4
(KCNK4) a two-pore potassium channel (K2P4.1) known as
TRAAK (TWIK-related arachidonic acid-stimulated K
+ channel)
and member 2 (KCNK2) a two-pore potassium channel (K2P2.1)
known as TREK-1 (TWIK-related K
+ channel) in human
myometrium [19] as did Bai et al. in the same year [20]. Given
these observations, we became interested in the regulation of
expression and signaling of these K2P channels in human
pregnancy myometrium in term and preterm labor. Since the
uterus undergoes unprecedented expansion and stretch during
gestation, we suggest that the stretch-activated K2P channels are
involved in the maintenance of uterine quiescence prior to the
onset of labor.
Stretch-activated K2P channels make up a unique subset of K
+
channels that are mechano-sensitive and belong to a larger family
of channels characterized by four transmembrane segments (TMS)
and two pore (2P) domain regions. Unlike other members of the
4TMS/2P channel family TREK-1, TREK-2, and TRAAK
belong to the TRAAK-family subset of K2P channels (KCNK2,
KCNK10 and KCNK4) that are activated by arachidonic acid
and increased membrane tension [21–23], both of which play a
role during parturition [24,25]. These channels which are thought
to form mature channels as homo- and or heterodimers, are also
known as leak or background K
+ channels and play an essential
role in setting the resting membrane potential of myocytes [23,26].
Examination of the literature reveals conflicting evidence for the
expression of these K2P channels in uterine muscle [18,20,27,28].
Therefore, the expression and differential regulation of TRAAK-
family channels during pregnancy and labor in human myome-
trium is of much interest, especially as they, or their regulation
may represent potential therapeutic targets in pre-term labor.
Here we report that TRAAK-family members TREK-1 and
TRAAK, but not TREK-2, are expressed in human pregnancy
myometrium and that TREK-1 is differentially regulated during
pregnancy. We provide evidence that inhibition of myometrial
K2P channels (i.e., TREK-1) increases uterine excitability while
activation of these channels lowers it. This work suggests that
TRAAK-family channels, especially TREK-1, may be important
in regulating uterine relaxation during pregnancy and hints at the
possible dysregulation of this mechanism in pre-term births.
Methods
Ethics Statement
The research presented here was reviewed and approved in
writing by the University of Nevada Biomedical Review
Committee (IRB) for the protection of human subjects in research.
Tissue Collection
With informed consent obtained in writing, samples of non-
pregnant and pregnant (laboring and non-laboring) uterine tissue
were obtained either via hysterectomy in pre-menopausal women
#43 y undergoing hysterectomy when no uterine pathology is
present, or elective cesarean section. Samples of non-pregnant
uterine tissue were taken from the mid body following inspection
by the pathologist, while samples from pregnant women were
taken from the upper portion of the transverse uterine incision.
Women were selected at random without inclusion criteria other
than a clinical decision to deliver a pregnancy by Caesarian
section (Table 1). Exclusion criteria were age less than 18 years,
multiple pregnancy, known illicit drug use, or HIV or hepatitis C
infection. Within 20 min of their removal, fresh tissue samples
were transported to the laboratory in cold physiological buffer
containing (in mM): NaCl (120), KCl (5), KH2PO4 (0.587),
Na2HPO4 (0.589), MgCl2 (2.5), Dextrose (20), CaCl2 (2.5), Tris
(25), and NaHCO3 (5), adjusted to pH 7.4. Tissues collected for
molecular biological studies were preserved and transported in
RNAlater (Ambion, Austin, TX). Tissue collection was approved
through the University of Nevada, Biomedical Institutional
Review Board (IRB).
Uterine smooth muscle (myometrium) was first dissected from
human uterine tissue samples and then either flash frozen in liquid
nitrogen and stored at 280uC for later analysis or immediately
utilized in contractile studies.
Semi-quantitative PCR
Total RNA was extracted from 50 mg (wet wt.) of myometrium
in TRIzol (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol and resuspended in 30 ml nuclease-free H2O.
DNA contamination was removed by treatment at 37uC with 10 U
RNAse-free DNAse I (Promega, Madison, WI). DNAse was
inactivated by adding 25 mM EDTA with heating at 55uC for
10 min. cDNA was synthesized from 1 mg of total RNA using
250 ng random primers (Invitrogen), 0.125 mM each dNTPs,
10 mM DTT and 200 U Superscript II reverse transcriptase
(Invitrogen).
Gene specific primers for human TRAAK, TREK-1, and
TREK-2 (Table 2) were designed from areas of high homology
between respective channel sequences from various published
Table 1. Patient characteristics-pre-gravid tissues.
Ethnicity Diagnosis
Age (y) White Latino A. Am.
Hysterectomy (38–43) 4 8 4 Elective (all without disease)
Patient Characteristics-Gravid Tissues
Term (38–41 wks.) (22–38) 9 13 5 Elective C-Section (all)
Term in Labor (39–40 wks.) (26–32) 4 7 2 Elective (8) Breech (3), Placenta Previa (2)
Preterm in Labor (26–34 wks.) (24–30) 2 0 3 PROM (2), Cervical Dilation .7 cm (3)
doi:10.1371/journal.pone.0012372.t001
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software (Coralville, IA). Basic local alignment search tool
(BLAST) searches were performed to confirm that primer
sequences had no homology with any other known gene products.
b-actin primers were designed to amplify both genomic (750 bp) as
well as non-genomic products (500 bp) to control for genomic
DNA contamination, while non-template controls ensured the
integrity of the PCR reaction. Amplification was performed with
the Quantum RNA 18S Internal Standards according to the
manufacturer’s protocol (Ambion). An optimized ratio (1:20) of
18S rRNA primers was added to the reaction as endogenous
standard along with competimer to modulate 18S amplification
without affecting the gene-specific PCR targets. PCR amplifica-
tion within the linear range was carried out in a thermocycler
under the following conditions: 95uC for 10 min as an initial melt,
followed by 40 cycles of 95uC for 45 sec, annealing between 58uC
to 60uC for 45 sec, and extension at 72uC for 45 sec; followed by a
final extension of 72uC for 5 min. We determined the linear range
of our PCR reactions by increasing cycle number and resolving
bands by electrophoresis. The products were visualized by
ethidium bromide staining and quantitated by computer. Cycle
number was plotted against the signal obtained in order to identify
the exponential (linear) range and the plateau phase. When cycle
number is plotted against the log of the signal, a straight line was
obtained. Human brain served as a positive control for channel
expression. PCR products were imaged with UV light on a gel-
documentation apparatus from Alpha-Innotech (San Leandro,
CA). K2P channel bands were quantified by densitometry and
expressed relative to bands of 18S rRNA controls which were
amplified in parallel from each sample. Nucleotide sequencing was
performed by the University of Nevada Genomics Center.
Quantitative Real Time PCR
Human myometrial tissues were homogenized in TRIzol
reagent, total RNA was isolated, and cDNA was synthesized as
described above from 25 mg (wet wt.) of myometrium and diluted
1:5. TREK-1 QPCR was carried out using SYBR I green dye and
TRAAK QPCR was carried out using Taqman gene expression
assays (Table 2; Applied Biosystems, Foster City, CA), both using
an ABI Prism 7000 sequence detection system.
Each SYBR green reaction (25 ml total) contained 2 ml cDNA
for 18S, 10 ml cDNA for TREK-1, 12.5 ml SYBR Green PCR 2X
Master Mix, and 400 nM forward and reverse primers. Samples
were heated to 50uC for 2 min, melted at 95uC for 10 min, and
then cycled 45 times at 95uC for 15 sec, followed by annealing and
extension at 58uC for 1 min. A single final dissociation step
included 95uC for 15 sec, 58uC for 20 sec, and 95uC for 15 sec.
Amplification of the message was monitored by measuring the
increase in fluorescence caused by SYBER I green binding to
double-stranded DNA, resulting in an amplification plot of
fluorescence vs. cycle number.
Each Taqman reaction (25 ml total) contained 2 ml cDNA for
18S, 8 ml cDNA for TRAAK, 12.5 ml Taqman Universal PCR 2X
Master Mix, 900 nM forward and reverse primers, and 250 nM
probe. Samples were heated to 50uC for 2 min, melted at 95uC for
10 min, and then cycled 45 times at 95uC for 15 sec and 60uC for
1 min. Amplification was monitored by measuring the increase in
fluorescence caused by the 59 to 39 nucleolytic activity of the
Amplitaq Gold enzyme cleaving the fluorescently-labeled probe,
resulting in an amplification plot of fluorescence vs. cycle number.
For both methods, standard curves were generated for each
target gene using serial dilutions of cDNA. The amount of specific
target genes in unknown samples was calculated by measuring the
cycle threshold (Ct) values and extrapolating starting copy
numbers from standard curves. All samples were tested in
triplicate and normalized to 18S rRNA amplified from respective
samples to control for variations in sample quality. Non-template
controls using water in place of cDNA were included in all QPCR
plates to ensure the integrity of reaction components.
Western Blotting
Flash frozen myometrial samples were homogenized and
sonicated in buffer consisting of 1% (v/v) Triton X-100,
150 mM NaCl, 10 mM NaH2PO4, 5 mM EDTA, and 1X
Halt
TM Protease Inhibitor Cocktail (Pierce, Rockford, IL). This
cell lysate was then centrifuged at 14,0006 g at 4uC for 30 min.
The supernatant from each sample was then tested for protein
concentration via Lowry assay (Bio-Rad, Hercules, CA) using
bovine serum albumin (BSA) as a standard.
Protein from lysate supernatants (30–40 mg) was boiled for
5 min in 1X denaturing sample loading buffer containing: 0.06 M
Tris-HCL (pH 6.8), 10% glycerol (v/v), 2% SDS (w/v), 0.03%
bromophenol blue (w/v), and 5% b-mercaptoethanol (v/v).
Proteins were separated by electrophoresis in 10% polyacrylamide
Table 2. PCR primers.
Gene GenBank Accession No. Semi-Quantitative PCR primer sequence Product size (bp)
TRAAK AF247042 F: 59-TCTCAAGGGCTTCGTTTCTGCTCT -93
R: 59-ATTGATGCAGGCTTTGAGGCACAG -93
240
TREK-1 NM_001017424 F: 59-TGGCTGTGTACTCTTTGTGGCTCT -93
R: 59-ACTCAGTCGCCTCCTGGTTTCTTT -93
349
TREK-2 NM_021161 F: 59-TTGTTGGCCTTGCCTACTTTGCAG -93
R: 59-ACACACACACACACACACACAACG -93
756
Gene GenBank Accession No. Quantitative PCR primer/probe sequence Product size (bp)
TREK-1 (SybergreenQPCR) AF129399 F: GGA ATT CCC CTC TTT GGT TTT C
R: CAC TTT GGC AAT TCC TTT TCC A
82
18S (Sybergreen QPCR) X03205.1 F: CAC GGC CGG TAC AGT GAA A
R: AGA GGA GCG AGC GAC CAA
72
TRAAK (TaqmanQPCR) NM_033310.2 TaqMan Gene Expression Assay Hs99999901_s1, Applied Biosystems 187
18S (TaqmanQPCR) X03205.1 TaqManGene Expression Assay Hs00213267_m1, Applied Biosystems 101
doi:10.1371/journal.pone.0012372.t002
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membrane. Membranes were blocked at 4uC overnight in a 1:1
solution of Odyssey
TM blocking buffer (Licor Biosciences, Lincoln,
NE) and phosphate buffered saline [PBS; 137 mM NaCl, 2.7 mM
KCl, 0.9 mM KH2PO4, 6.4 mM Na2HPO4, adjusted to pH 7.4].
The membranes were then labeled for either human TREK-1
(1:1000 rabbit IgG; Santa Cruz Biotechnology, CA) or TRAAK
(1:1000 goat IgG; Santa Cruz Biotechnology). Respective
secondary antibodies conjugated to either infrared 680 or infrared
800 fluorescent dye (1:100,000; Invitrogen or Rockland Immuno-
chemicals, Philadelphia, PA) were used for detection. Antibody
incubations were carried out in 1:1 Odyssey
TM blocking buffer
(Licor Biosciences) and PBS with 0.1% Tween-20 (v/v) at 4uC.
Bands were visualized using an infrared imaging system (LI-COR
Biosciences V2.04, NE) using both the 700 nm and 800 nm
channels. Relative protein levels were quantified via densitometry
and normalized to GAPDH (1:1500 mouse IgG; Santa Cruz
Biotechnology) for each individual sample.
Human brain was utilized as a positive for both TREK-1 and
TRAAK protein expression. Cos-7 cells over-expressing TREK-1
were employed as an additional positive control for TREK-1
protein detection [29], as well as a negative cross reactivity control
for TRAAK protein detection. Cos-7 cells were maintained in
Dulbecco’s Modified Eagle Media (DMEM) supplemented with
10% fetal bovine serum (FBS). TREK-1 Cos cell lysate
supernatant was obtained and probed as with human myometrial
samples.
Contractile Studies
Fresh non-laboring and laboring pregnant human uterine
smooth muscle was dissected in Krebs buffer without Ca
+2 so
that only myometrium was present. Myometrium was cut into thin
strips (165 mm), mounted in organ baths (Radnoti, Monrovia,
CA), and attached to isometric force transducers (Kent Scientific,
Litchfield, CT) by metal clips. Once mounted, tissues were bathed
in Krebs buffer with Ca
+2 [(in mM): NaCl (118), KCl (4.75), CaCl2
(2.5), KH2PO4 (1.2), NaHCO3 (25), MgSO4 (1.2), dextrose (20),
adjusted to pH 7.4] and maintained at 37uC, aerated with 95%
O2/5% CO2, and loaded with initial tensions of 1.8 g force as we
have previously described [19,30]. During the course of a 1 hr
equilibration period, all tissues were routinely challenged with
oxytocin (OT, 100 nM) followed by washout after which, tissues
became spontaneously active. Stretch-activated channel toxin,
GsMTx-4 (Peptides, International, KY) was added to baths at
concentrations ranging from 0.9 mM to 3.6 mM, while L-
Methionine ethyl ester (L-Mee) was tested between the range of
30 mM to 10 mM and fluphenazine was employed at 100 mM.
Iberiotoxin (100 nM) was applied to all tissues to inhibit large-
conductance calcium activated K
+ channels. Transducer voltages
were amplified and converted to digital signals by an analogue-to-
digital board mounted within a computer system running the
DASYLab data acquisition system (V10.0; IOtech, OH). Tissue
contraction was compared and normalized to its own basal relaxed
(control) state; contractility in the presence of varying levels of
GsMTx-4 or L-Mee was quantified by comparing frequency of
contraction or tension generated (grams) over time. GsMTx-4 has
been reported to be a specific stretch-activated channel inhibitor
[31,32], while L-methionine and fluphenazine show reasonable
selectivity as TREK channel antagonists [17,33,34].
Statistical Analyses
All graphs were prepared using Prism Graphing Software
(V5.01; GraphPad Software, CA) and power calculations and
statistical analyses were carried out using Statmate and InStat
Statistical Software (GraphPad Software, CA), with p#0.05
considered significant. Significance was determined using either
non-parametric analysis of variance (Kruskal–Wallis) with Dunn’s
multiple comparisons post-test or nonparametric t-test (Mann–
Whitney). Data points and error bars represent means 6 S.E.M.
*, p#0.05; **, p#0.01; ***, p#0.001 (between groups). For protein,
transcript, and contractile experiments, the number of different
patients and their respective myometrial tissue is denoted by ‘n’.
Results
TRAAK Gene and Protein Expression in Human
Myometrium
Relative myometrial TRAAK mRNA expression was deter-
mined by PCR and normalized to b-actin expression (Fig. 1A).
TRAAK primers (Table 2) gave a 240 base pair transcript found
to be expressed in both pregnant and non-pregnant human
myometrial smooth muscle (Fig. 1B) at similar levels. Human
brain was included as a positive control for TRAAK expression.
The TRAAK PCR product was subsequently purified and
sequenced by the Nevada Genomics Center and compared with
known sequence using BLAST (National Center for Biotechnology
Information) to further confirm its identity (98% identity). We
determined that both pregnant and non-pregnant human
myometrial smooth muscles express TRAAK with comparable
abundance using this technique suggesting that there is no up-
regulation of TRAAK channel gene expression during gestation
(Fig. 1B).
In order to determine whether or not TRAAK expression in
pregnant myometrium might be regulated at the time of labor, we
used quantitative PCR (Fig. 1C). Myometrial gene expression was
determined as normalized for expression of 18S ribosomal RNA
that we have previously shown to be stable in non-pregnant versus
pregnant myometrium [15]. A difference in TRAAK gene
expression in laboring tissues taken from 13 women at term (39–
40 weeks gestation) versus non-laboring tissues taken from 27
women at term (38–41 weeks gestation) was not significant. Power
analysis confirmed that we would measure a difference if one
existed at this level with 99% power to detect a significant
difference at p=0.05.
TRAAK protein expression in myometrial samples was
determined using Western blot (Fig 2A). Control experiments
using TREK-1 over expressing COS cells demonstrated that the
TRAAK antibody (Santa Cruz, CA) was specific for TRAAK
expression (data not shown). TRAAK antibody revealed a single
band at 47 kDa (under reducing conditions) and immunoblots
were developed for GAPDH as a loading control and to normalize
TRAAK expression (Fig. 2A). No significant difference was found
in the expression of TRAAK in 17 term pregnant samples (38–40
weeks gestation) compared to 16 samples from non-pregnant
myometrium (pre-menopause; age #43 yr) consistent with the
results of gene expression for TRAAK (Fig. 1A). In a larger group
of pregnant samples from both term (38–41 weeks gestation) and
term laboring myometrium (38–41 weeks), no difference in
TRAAK protein expression (Fig. 2B) was confirmed, consistent
with gene expression data (Fig. 1C).
TREK-1 Gene and Protein Expression
TREK-1 mRNA was expressed in both non-pregnant and
pregnant human myometrial smooth muscle (Fig. 1A). Amplifica-
tion of TREK-2 message from either non-pregnant or pregnant
human myometrium yielded no evidence of expression consistent
with the findings of Bai, et al. [20]. Ribosomal 18S RNA was used
to normalize PCR reactions [15]. Expression of TREK-1 in
Human Myometrial K2P Channels
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myocyte proteins (Fig 3A). TREK-1 mRNA expression varied
significantly between non-pregnant and pregnant myometrium,
demonstrating a ,2 fold up-regulation during pregnancy toward
term (70.2 vs. 134.2%; p,0.01; Fig. 3B) suggesting the possibility
that TREK-1 plays a role during pregnancy. In order to determine
the effect of labor at term, TREK-1 gene expression was examined
in these patient samples by Q-PCR. The elevated expression seen
in pregnant term samples when compared to laboring term
samples revealed a dramatic decrease in gene expression consistent
with the notion that TREK-1 contributes to myometrial
quiescence at term (Fig. 3C). Because the absence of TREK-1
could contribute to preterm labor, we also determined TREK-1
expression in samples from women in labor at 28–33 weeks
gestation. TREK-1 gene expression in preterm myometrium
(Fig. 3C) was comparable to expression in laboring samples.
Figure 1. TRAAK K2P channel expression in human myometri-
um. (A) PCR studies were carried out on both non-pregnant and
pregnant tissues and human brain. (NTC, non template control). (B)
Human brain served as a control and b-actin (500 bp) was used to
adjust TRAAK gene expression (240 bp) relative to control gene
expression. PCR transcripts at 240 base pairs were sequenced and
matched known TRAAK sequence. (C) Expression of TRAAK in term and
term laboring samples and in brain as a comparative control was
determined by Q-PRC with the 18S ribosomal gene as an expression
control.
doi:10.1371/journal.pone.0012372.g001
Figure 2. TRAAK protein expression in human myometrium. (A)
Western blots were performed using a TRAAK-specific antibody (Santa
Cruz) and stained using infrared fluorescence secondary from Licor
BiosciencesH. Individual lanes represent different patient samples and
are shown to illustrate representative variation. GAPDH was employed
as an expression control using simultaneous imaging. TRAAK expres-
sion is not increased by pregnancy compared to non-pregnant samples,
nor was there any effect of labor (B). Representative Western blots are
shown along with average data. Experiments were repeated three times
on the same sample set and the results averaged for each sample. Data
are Mean 6 SEM compared by one-way analysis of variance.
doi:10.1371/journal.pone.0012372.g002
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was confirmed in both pregnant and non-pregnant tissue samples
(Fig. 4A) by Western blot quantified for both TREK-1 (48 kDa
under reducing conditions) and GAPDH. TREK-1 protein
expression showed a significant increase during pregnancy (26%,
Fig. 4A) consistent with gene expression data (Fig. 3B). At the time
of labor however, TREK protein expression measured by Western
blot is still present at pre-laboring levels but is significantly lower in
preterm samples (Fig. 4B).
Figure 3. TREK-1 K2P channel expression in myometrium. (A)
PCR studies were carried out on both non-pregnant and pregnant
tissues and cells from term pregnancy myometrium and TREK-1
transcript confirmed by sequence analysis in each case. Individual
lanes represent different patient samples and are shown to illustrate
representative variation. (B) 18S ribosomal RNA was used to adjust TREK
gene expression relative to control gene expression. (C) Expression of
TREK in term and term laboring samples was determined by Q-PRC
relative to the 18S ribosomal gene as an expression control (p,.001).
Data are mean 6 SEM; ** =p,0.01; *** = p,0.001 by unpaired T-test.
doi:10.1371/journal.pone.0012372.g003 Figure 4. TREK-1 protein expression in myometrium. (A) Western
blots were performed using a TREK-1-specific antibody (Santa Cruz) and
stained using infrared fluorescence secondary. GAPDH was employed as
an expression control using simultaneous imaging. Individual lanes
represent different patient samples and are shown to illustrate
representative variation. TREK-1 expression is significantly increased
by pregnancy compared to non-pregnant samples and, (B) remains
unchanged during labor but expression is lower in preterm samples.
Data are mean 6 SEM, * = p,0.05; *** = p,0.001 by unpaired T-test.
doi:10.1371/journal.pone.0012372.g004
Human Myometrial K2P Channels
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Myometrial Contractions
To verify the significance of stretch-activated channels to the
physiological function of the myometrium, we explored the effects
of inhibiting stretch-activated channels. In order to test the
hypothesis that stretch-activated channels assist in the regulation of
phasic contractions in myometrial smooth muscle, we utilized
contractile bath studies. Increasing concentrations of GsMTx-4
(Grammostola spatulata mechanotoxin-4), a specific mechanosen-
sitive channel blocker [35], amplified oxytocin (1 mM; OT)
induced contractions in non-laboring pregnant myometrium.
Addition of GsMTx-4 at 0.9 mM caused an increase in duration
of contractions (Fig. 5A), while higher concentrations such as
1.8 mM toxin caused both an increase in duration and frequency
of contractions (Fig. 5B). This effect was not seen on spontaneously
contracting tissue strips (control, no OT treatment) and the degree
of effect varied greatly from patient to patient but was consistently
seen (data not shown).
Because GsMTx-4 affects all stretch-activated channels and thus
in myometrium blocks both TREK-1 and TRAAK, we further
tested the hypothesis that a TREK-1 more specific stretch-
activated potassium channel inhibitor would diminish the ability of
the myometrium to relax. It has been shown in bladder smooth
muscle that methionine and its derivatives inhibit TREK channels,
thereby increasing bladder excitability [17,33]. We observed that
increasing concentrations of L-methionine ethyl ester (L-Mee)
augmented spontaneous contractions in non-laboring myometri-
um. Addition of L-Mee at 300 mM caused an increase in
frequency of contractions (Fig. 6). We further normalized each
tissue to itself under control conditions (100 nM iberiotoxin) and
observed that L-Mee increased myometrial frequency of contrac-
tion in a dose dependent manner (Fig. 6B). L-Mee significantly
inhibited myometrial relaxation (i.e. increased contractions) at
concentrations $100 mM( p#0.05) and reached maximal effect at
,300 mM where contractile frequency was increased to ,35%
above control levels (Fig. 6C). At concentrations of L-Mee
$1 mM we observed a reduction in peak contraction amplitude
and a diminished ability for tissue recovery after washout of drug;
tissues treated with 10 mM L-Mee failed to contract or relax (data
not shown).
Fluphenazine and other antipsychotics have also been described
as selective K2P blockers able to inhibit TREK-1 but not TRAAK
channels [34]. We conducted contractile bath experiments in
pregnant tissues using the K2P channel activator arachidonic acid
(AA; 10 mM) and the putative TREK-1 inhibitor fluphenazine
(FLU; 100 mM). OT (100 nM) stimulated contractions (ex. Fig. 6A)
were blunted by the addition of AA compared to control consistent
with TREK-1 channel activation (Fig. 6C). Addition of fluphen-
azine alone did not significantly alter contractility, while addition
of FLU to oxytocin treated tissues in the presence of AA prevented
the diminished contractility seen with AA alone (Fig. 6C). Tissues
responded to OT stimulations in a fashion comparable to control
after washout of AA and FLU (Fig. 6C. Post-Con). Concentrations
of FLU greater than 300 mM suppressed OT-induced contractions
and were irreversible during the course of the experiment
suggesting non-specific effects (not shown).
Discussion
While many factors are thought to modulate the contraction
and relaxation of uterine smooth muscle, it is generally agreed that
membrane ion channels are crucial to this process and are likely
targets of many of the factors which regulate myometrial tone.
Interest in stretch-activated channels in the myometrium stems
from the knowledge that the uterus enlarges to accommodate a
growing fetus during pregnancy. Evidence supports the general
notion that potassium channels maintain the uterus in a quiescent
state during gestation [36]. We further hypothesized that stretch
activated potassium channels are differentially regulated and
contribute substantially to the resting membrane potential in the
pregnant myometrium, as well as serving to counteract contractile
stimuli. We were therefore interested in elucidating the role and
possible regulation of the stretch-activated channels, TREK and
TRAAK. These channels and the factors that regulate them may
provide a unique therapeutic target to regulate the contractility of
the myometrium in cases such as preterm labor.
The stretch-activated channel TREK-1 was previously reported
to only be minimally expressed in human myometrium [20,28,37],
while the K2P channels TREK-2 and TRAAK were thought not
to be expressed in this tissue at all [18,20,38]. Here we report that
TREK-1 and TRAAK, but not TREK-2, transcripts and protein
are expressed in human myometrium. Furthermore, TREK-1 but
not TRAAK is substantially up-regulated in pregnant samples
when compared to non-pregnant samples consistent with a
functional role for TREK-1 channels in pregnancy. The stretch-
activated channel toxin (GsM Tx-4) and the TREK-1 more
selective channel inhibitors methionine ethyl ester and fluphen-
azine altered myometrial tension and contractile frequency
Figure 5. GsMTx-4 increases OT-induced contractions. Contrac-
tile bath experiments using the specific stretch-activated channel
blocker, GsMTx-4 at doses of 0.9 to 1.8 mM, in the presence of OT were
performed to observe the effect on non-laboring myometrium. OT-
induced (1 mM) contractions were established, followed by a wash-out
period. Tissue was then challenged with A) 0.9 mM GsMTx-4, causing
increased duration of contractions, or (B) 1.8 mM GsMTx-4, causing
attenuation of relaxation. Traces are representative of n=4.
doi:10.1371/journal.pone.0012372.g005
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myometrium. Increased TREK-1 channel expression as well as
function in pregnant myometrium suggests that as pregnancy
progresses and the stretch of the uterus increases, these K2P
channels are activated to assist in the maintenance of relaxation.
To the best of our knowledge, ours is the first work documenting
the expression and action of TREK in the myometrium during
human pregnancy and labor. This report of a regulated increase in
both expression as well as channel function supports our
hypothesis that TREK-1 channels are important in maintaining
quiescence during pregnancy and that channel expression and or
activation may be dysregulated in spontaneous pre-term labor.
This notion of differential expression of TREK-1 channels and
their regulation of membrane excitability in normal physiology is
supported by several reports in animal models. Differential
regulation of TREK-1 has been shown in epicardial vs.
endocardial myocytes in rat ventricle [39]. TREK-1 has further
been observed to be developmentally regulated in rat ventricle
Figure 6. L-methionine ethyl ester increases frequency of contraction in a dose-dependent manner. L-Mee increased contractile
frequency in non-laboring myometrial strips in a concentration-dependent manner (30 mM to 300 mM). Iberiotoxin (100 nM) was present to block
Ca
2+-activated currents and tissues established spontaneous contractions before drug addition. (A) 30 mM L-Mee applied to the bath caused a slight
increase in frequency of contraction, with recovery after washout. (B) 100 mM L-Mee caused a significant increase in frequency of contraction that was
pronounced at 300 mM L-Mee with recovery after washout; 1 mM L-Mee caused a marked increase in frequency of contraction with modest, variable
reduction in peak amplitude that remained after washout (not shown). (C) In a similar set of tissues, arachidonic acid (AA) significantly depressed
contractions, an effect blocked by fluphenazine (FLU; 100 mM), while addition of fluphenazine alone had no significant effect. The effect of L-Mee to
increase contractions was not different when added in the presence of 100 mM AA (not shown). Tissues returned to control tension after washout.
Data are mean 6 SEM, ** = p,0.05, n=7.
doi:10.1371/journal.pone.0012372.g006
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hyperpolarizing effect [40]. Evidence also suggests the regulation
of K2P channel expression and function in pathophysiological
states. Elevated levels of TREK-1 mRNA and protein have been
seen in hypertrophic myocardium [41]. TREK-1 and TRAAK
have also been shown to be up-regulated in a rat model of
experimental acute cerebral ischemia [42].
It is known that ischemia can activate phospholipase A2 and
result in the accumulation of unsaturated fatty acids such as
arachidonic acid. Accumulation of arachidonic acid would lead to
activation of TREK, thereby causing an efflux of K
+ and allow for
membrane hyperpolarization to decrease cell excitability. This
mechanism is hypothesized to provide a neuroprotective effect
during cerebral ischemia and may parallel the mechanism by
which we hypothesize the up-regulation of myometrial TREK-1
channels during gestation to help maintain the uterus in a relative
state of quiescence.
Blockade of stretch-activated channels by GsMTx-4 in pregnant
human myometrium increased contractions and subsequently
attenuated normal relaxation mechanisms in non-laboring tissues.
Stretch-activated K
+ channels are likely to be significant
contributors to the relaxed state in pregnancy because activation
by arachidonic acid lowers myometrial tension in oxytocin-
stimulated tissues, an effect blocked by fluphenazine while
fluphenazine alone had no effect in our studies. Inhibition by L-
Mee increases contractile frequency in non-laboring tissues
consistent with removal of a relaxation influence on the muscle.
Our findings are consistent with previous studies showing the
inhibition of TREK-1 channels by methionine containing
compounds or fluphenazine [17,33,34]. The mechanism of
TREK-1 activation and inhibition in human myometrium is
unknown and thus the failure of fluphenazine to alter contractions
when added alone and yet block an effect of arachidonic acid are
unexplained. These results may reflect distinctions in the manner
of channel inhibition by these agents.
There is a clear dissociation between TREK-1 gene expression
and protein expression in the samples tested (Fig. 3C vs. 4B). If our
thesis is correct, this result may not reveal a distinction between
gene regulation, reduced at the time of labor, and the presence of
protein detectable in Western blots. While it is entirely likely that
the time needed to see a fall in protein following changes in gene
expression may not be provided for in laboring tissues, it is also
possible that we do not detect labor-associated regulation of
channel function such that continued presence of the protein is not
inconsistent with labor. The decreased expression of both message
and protein in preterm tissues however (Fig. 3C, 4B) is consistent
with our hypothesis. Potassium channel internalization (a state of
the channel not reflected by gene or protein expression), has been
shown to be affected by post-translational modifications which can
be differentially regulated depending on metabolic states [43–45].
In addition to regulation of K2P channels via expression levels and
post-translational modulation, reports also support the presence of
splice variants with differing channel activity. Alternative splicing
of potassium channels has previously been shown to contribute to
the diversity of channel specificity in myometrium [36,46–48], as
well as many other tissues [49–52]. More importantly, TREK-1
has been shown to be alternatively spliced in rat heart suggesting
two different channel isoforms; one of lower (,41 pS) and one of
higher (,132 pS) conductance, both stimulated at positive
potentials [53]. This information, as well as a survey of available
TREK-1 sequence variants on GenBank, leads us to hypothesize
alternative splicing of TREK-1 in differing states of the uterus; a
dysregulation or shift in predominant variant(s) and or assembly of
channels as homo- or heterodimers in a regulated fashion by
pregnancy may explain TREK-1 activation in pregnancy
myometrium and alterations in this process may predispose
certain women to spontaneous pre-term labor contributing to
pre-term birth.
Difference in the expression of TREK-1 seen in pregnant versus
non-pregnant myometrium are not thought to be the result of the
age difference in patients in these two groups (Table 1). The fact
that TRAAK expression was not different argues in favor of age
not being a factor. However, age is significantly different between
pre-gravid and gravid women but does not represent power
sufficient to support a comparison of age difference in each
pregnancy group versus pre-gravid women. We do not think it
likely that age per se, influences our results.
In summary, our results provide strong evidence supporting the
hypothesis that the K2P channel TREK-1 is functionally up-
regulated in pregnancy, and differentially regulated during
pregnancy to relax the uterus prior to labor. We hypothesize that
TREK-1 is functionally dysregulated in spontaneous pre-term
birth, contributing to the disruption of normal myometrial
quiescence during pregnancy. This dysregulation may be the
result of changes in channel expression levels, post-translational
modulation and/or variant channel expression and dysfunctional
channel assembly. TREK-1 channels and or their regulation offer
promise as potential therapeutic targets in controlling pre-term
uterine contractions.
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